Chargement en cours...
Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes
Sodium-glucose cotransporter 2 (SGLT2) inhibitor clinical studies in type 1 diabetes mellitus (T1DM) have demonstrated reduced HbA1c and lower glucose variability with increased time in optimal glucose range as well as additional benefits of reductions in weight and insulin dose without increasing t...
Enregistré dans:
| Publié dans: | Diabetes Ther |
|---|---|
| Auteurs principaux: | , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Springer Healthcare
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6965597/ https://ncbi.nlm.nih.gov/pubmed/31813092 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-019-00728-6 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|